AVITA Medical, Inc.

NASDAQ:RCEL

Medical - Devices

Healthcare
$16.83 -0.25%

+$0.00 today

Market cap
$418.11M
Beta
1.86
P/E (TTM)
-0.0
EPS (TTM)
-$148.45
52W Low $3.22High $7.12

Volume 0.72M

Average 0.24M

RCEL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

AVITA Medical, Inc.NASDAQ: RCEL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $15.73M rose 0.3% year over year, ahead of the -3.9% change in trailing-twelve-month gross profit. Sequentially, it rose 9.9% from the prior quarter. Over 3 fiscal years it compounded at +27.5% a year.

Context

  • Gross profit amounted to 82.1% of revenue in FY2025, down 3.7 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.3% holds above the trailing-twelve-month pace of -3.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.73M+9.9% QoQ
Last fiscal yearDec 2025
$58.82M+6.6% YoY
LTMMar 2026
$58.86M-3.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.3%——
1 year+6.6%——
3-year CAGR+27.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
58.82M USD
Year-over-year change
+6.6%
4-year CAGR
+21.6%

Gross Profit vs competitors

How RCEL compares with its peers on the latest reported figures

  • RCEL's LTM Mar 2026 gross profit of $58.86M is the 2nd highest of the 9 companies compared; the peer median is $7.47M.
  • Its year-over-year change of -3.9% is the 6th highest of 9, against a peer median of +3.3%.
  • Gross profit amounts to 81.4% of revenue for RCEL, versus a peer median of 51.2%.
RCEL Competitors Peer median
Gross Profit for RCEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$76M +6.8%+37.9%62.3%
RCELAVITA Medical, Inc.LTM Mar 2026$58.86M -3.9%+27.5%81.4%
FONRFONAR CorporationLTM Mar 2026$42.41M -0.1%-3.0%40.3%
APYXApyx Medical CorporationLTM Mar 2026$18.04M -26.0%-13.2%32.3%
HYPRHyperfine, Inc.LTM Mar 2026$7.85M +44.8%+95.3%51.2%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.09M +1193.2%+66.6%99.5%
VANIVivani Medical, Inc.LTM Mar 2026-$130K -46.1%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K -146.7%—82.0%
LUCDLucid Diagnostics Inc.LTM Mar 2026-$2.06M +27.2%—40.0%
Peer median (excluding RCEL) $7.47M+3.3%+37.9%51.2%

Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.03M34.42M50.14M64.25M71.61M
Cost of Revenue6.1M6.04M7.78M9.09M12.79M
Gross Profit26.92M28.38M42.36M55.16M58.82M
Gross Margin81.5%82.4%84.5%85.8%82.1%
Research & Development15.67M13.86M20.82M20.36M20.84M
Selling, General & Admin37.21M45.24M65.63M91.39M79.91M
Operating Expenses52.04M55.89M85.02M111.75M100.75M
Depreciation & Amortization673K568K632K1.13M2.35M
EBITDA(24.4M)(26.05M)(33.54M)(55.3M)(39.59M)
EBITDA Margin-73.9%-75.7%-66.9%-86.1%-55.3%
Operating Income(25.12M)(27.51M)(42.66M)(56.59M)(41.93M)
Operating Margin-76.1%-79.9%-85.1%-88.1%-58.6%
Interest Income00000
Interest Expense29K16K1.14M5.36M5M
Other Income / Expenses18K876K7.34M(5.2M)(6.64M)
Income Before Tax(25.1M)(26.63M)(35.32M)(61.79M)(48.58M)
Pre-Tax Margin-76.0%-77.4%-70.4%-96.2%-67.8%
Income Tax Expense42K36K66K54K11K
Net Income(25.14M)(26.67M)(35.38M)(61.85M)(48.59M)
Net Margin-76.1%-77.5%-70.6%-96.3%-67.8%
EPS (Basic)(1.03)(1.07)(1.40)(2.39)(1.74)
EPS (Diluted)(1.03)(1.07)(1.40)(2.39)(1.74)
Weighted Avg Shares24.36M25M25.33M25.88M27.86M
Weighted Avg Shares (Diluted)24.36M25M25.33M25.88M27.86M

AVITA Medical, Inc.

NASDAQ:RCEL

Intrinsic Alpha fair value

Locked

Current Price

$16.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.